# US 2022/0025067 A1 · Highly efficient anti-tfpi antibody composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0025067 A1
- Document ID: US20220025067A1
- Status: Published application
- Kind: A1
- Application number: 17/276,276
- Filed: 2019-09-06
- Published: 2022-01-27
- Earliest claimed: 2018-09-21
- Assignees: The Green Cross Corporation
- Applicants: Green Cross Corporation
- Inventors: Min Jung KIM; Geun Hye YEO; Haeng Eun SONG; Ji Yoon PARK; Yuna KIM
- Web page: https://patentgrep.com/patent/US20220025067A1

## CPC

- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C07K 16/38: against protease inhibitors of peptide structure
- C07K 1/165: {mixed-mode chromatography}
- C07K 1/22: Affinity chromatography or related techniques based upon selective absorption processes
- C07K 1/34: by filtration, ultrafiltration or reverse osmosis
- C07K 1/36: by a combination of two or more processes of different types
- C07K 16/065: {Purification, fragmentation}
- C07K 2317/10: characterized by their source of isolation or production
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/21: from primates, e.g. man
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to a pharmaceutical highly efficient anti-TFPI antibody composition including an anti-TFPI antibody for treating hemophilia, in which the content of HCP in a drug substance is less than 10.0 ng/mg, and the content of LPA in the drug substance or the drug product is less than 1.0 ng/mg. According to the present disclosure, a highly efficient anti-TFPI antibody composition having very low contents of HCP and LPA may be provided by providing a separation/purification process capable of minimizing anti-TFPI antibody polymer generation, and may be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease.

## Claims

### Claim 1

A pharmaceutical composition comprising an anti-tissue factor pathway inhibitor (anti-TFPI) antibody, a content of host cell protein (HCP) is less than 10.0 ng/mg, and a content of leachable protein A (LPA) is less than 1.0 ng/mg.

### Claim 2 (depends on 1)

The composition of claim 1, wherein a total content of HCP and LPA is 5 ng/mg or less.

### Claim 3 (depends on 1)

The composition of claim 1, which is produced through:
(a) a process of clarifying a culture containing the anti-TFPI antibody to obtain a clarified culture; followed by following (b)-(g):
(b) an affinity chromatography process;
(c) a viral inactivation process;
(d) an ultrafiltration and diafiltration process;
(e) a mixed-mode chromatography process;
(f) a nano-filtration process; and
(g) a concentration process.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the mixed-mode chromatography process comprises removing 98% or more of a polymer of the anti-TFPI antibody by performing two or more plural mixed-mode chromatography processes using different types of column resin.

### Claim 5 (depends on 3)

The composition of claim 3, wherein the affinity chromatography process comprise the steps of:
neutralizing an eluate, which passed through an affinity chromatography column, in the range of pH 4.0 to 6.0; and
leaving the neutralized eluate to stand at a temperature of 15 to 25° C.) for 8 to 16 hours.

### Claim 6 (depends on 3)

The composition of claim 3, wherein the concentration process comprises a rinse solution circulation/recovery process.

### Claim 7 (depends on 1)

The composition of claim 1, wherein a content of the anti-TFPI antibody in a form of polymer is less than 5%.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the composition has an EC50 value of 3.26 ng/mL or less.

### Claim 9 (depends on 3)

The composition of claim 3, wherein the content of HCP in the composition after purification of (b)-(g) is at least 50,000-fold lower than the content of HCP in the clarified culture obtained in (a).

### Claim 10 (depends on 1)

The composition of claim 1, wherein the relative potency value of the composition is 85% or higher compared to that of 100% monomer.

### Claim 11

A method of preparing a pharmaceutical composition comprising a purified anti-tissue factor pathway inhibitor (anti-TFPI antibody), wherein a content of host cell protein (HCP) in the composition is less than 10.0 ng/mg, and a content of leachable protein A (LPA) in the composition is less than 1.0 ng/mg,
said purified anti-TFPI antibody being obtained by a method comprising
(a) a step of clarifying a culture containing the anti-TFPI antibody to obtain a clarified culture, wherein the clarified culture is subjected to following (b)-(g);
(b) an affinity chromatography process;
(c) a viral inactivation process;
(d) an ultrafiltration and diafiltration process;
(e) a mixed-mode chromatography process;
(f) a nano-filtration process; and
(g) a concentration process.

### Claim 12 (depends on 11)

The method of claim 11, wherein a total content of HCP and LPA in the composition is 5 ng/mg or less.

### Claim 13 (depends on 11)

The method of claim 11, wherein the mixed-mode chromatography process comprises removing 98% or more of the anti-TFPI antibody in a form of polymer by performing two or more plural mixed-mode chromatography processes using different types of column resin.

### Claim 14 (depends on 11)

The method of claim 11, wherein the affinity chromatography process comprise the steps of:
neutralizing an eluate, which passed through an affinity chromatography column, in the range of pH 4.0 to 6.0; and
leaving the neutralized eluate to stand at a temperature of 15 to 25° C. for 8 to 16 hours.

### Claim 15 (depends on 11)

The method of claim 11, wherein the concentration process comprises a rinse solution circulation/recovery process.

### Claim 16 (depends on 11)

The method of claim 11, wherein a content of the anti-TFPI antibody in a form of polymer in the composition is less than 5%.

### Claim 17 (depends on 11)

The method of claim 11, wherein the composition has an EC50 value of 3.26 ng/mL or less.

### Claim 18 (depends on 11)

The method of claim 11, wherein the HCP content in a composition obtained after a purification comprising (b)-(g) is at least 50,000-fold lower than the HCP content in the clarified culture obtained in (a) and before the purification.

### Claim 19 (depends on 11)

The method of claim 11, wherein a relative potency value of the composition is 85% or higher compared to that of the composition in which 100% of the anti-TFPI antibody is in a form of monomer.
